Used in research for the treatment of type 2 diabetes, BAY 869766 acts as a selective inhibitor of the sodium-glucose co-transporter 2 (SGLT2). By blocking SGLT2 in the kidneys, it reduces glucose reabsorption, leading to increased excretion of glucose through urine and lower blood sugar levels. This mechanism offers a potential therapeutic approach that is independent of insulin action, making it suitable for patients with impaired insulin function. It has been studied in clinical trials to evaluate its efficacy, safety, and impact on glycemic control.